Schaiquevich Paula, Niselman Ada, Rubio Modesto
Instituto de Investigaciones Farmacológicas (ININFA-CONICET), Universidad Nacional de Buenos Aires, Junín 956 5 composite functionpiso (1113), Buenos Aires, Argentina.
Pharmacol Res. 2002 May;45(5):399-405. doi: 10.1006/phrs.2002.0954.
The plasmatic profiles of 12 healthy volunteers after oral administration of ranitidine (150 mg) were studied considering two compartmental models. We observed the presence of two peaks. The proposed mechanism responsible for the existence of secondary peaks includes enterohepatic recirculation and the existence of multiple sites of absorption along the gastrointestinal tract. For characterizing the pharmacokinetic aspect of the drug, both phenomena were described using two compartmental models. We calculated the pharmacokinetic parameters and statistical tests after fitting the data of each volunteer under both models proposed. Statistically significant differences were not found in the statistical test values but existed in the area under the curve (AUC) comparing between models. To decide which of the two proposed models gave the best approximation of the physiological phenomenon undergone, we studied the pharmacokinetic of the drug in the rat, an animal without gallbladder. After oral administration of ranitidine, the plasmatic profile of the animals showed at least two peaks. Less than 0.2% of an oral dose was recovered in bile as ranitidine. Therefore, and considering the rat has no post-absorptive depot from where the drug can be released discontinuously, enterohepatic recycling does not seem to contribute significantly to the occurrence of secondary peaks in the concentration-time profiles of rats. Considering the results, we proposed that the best model able to explain the plasmatic profiles found in man and rats after oral administration of ranitidine is the one that presents multiple sites of absorption along the gastrointestinal tract. It is important to define the correct model in the calculation of the AUC and so in the value of the absolute bioavailability.
采用二室模型研究了12名健康志愿者口服雷尼替丁(150毫克)后的血浆药代动力学特征。我们观察到有两个峰。导致出现第二个峰的推测机制包括肠肝循环以及胃肠道沿线存在多个吸收位点。为了表征该药物的药代动力学特征,使用二室模型描述了这两种现象。在对所提出的两种模型下每名志愿者的数据进行拟合后,我们计算了药代动力学参数并进行了统计检验。统计检验值未发现统计学上的显著差异,但在比较不同模型时曲线下面积(AUC)存在差异。为了确定所提出的两种模型中哪一种能最好地近似所经历的生理现象,我们研究了该药物在大鼠(一种无胆囊动物)中的药代动力学。口服雷尼替丁后,动物的血浆药代动力学特征显示至少有两个峰。作为雷尼替丁,在胆汁中回收的口服剂量不到0.2%。因此,考虑到大鼠没有吸收后储存库,药物不能从那里间断释放,肠肝循环似乎对大鼠浓度 - 时间曲线中第二个峰的出现没有显著贡献。基于这些结果,我们提出,能够解释口服雷尼替丁后在人和大鼠中发现的血浆药代动力学特征的最佳模型是那种在胃肠道沿线存在多个吸收位点的模型。在计算AUC以及绝对生物利用度的值时定义正确的模型很重要。